Cerivastatin西立伐他汀钠,143201-11-0

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Cerivastatin sodium

CAS No. : 143201-11-0

MCE 国际站：Cerivastatin sodium

产品活性：Cerivastatin sodium 是一种合成的降脂剂，是一种高效，耐受性好，口服活性的 HMG-CoA 还原酶抑制剂，Ki 为 1.3 nM/L。Cerivastatin sodium 可降低低密度脂蛋白胆固醇水平。Cerivastatin sodium 还主要通过 RhoA 抑制作用来抑制 MDA-MB-231 细胞的增殖和侵袭，具有抗癌作用。

研究领域：Metabolic Enzyme/Protease  |  Apoptosis

作用靶点：HMG-CoA Reductase (HMGCR)  |  Ferroptosis

In Vitro: Cerivastatin sodium (5-50 ng/mL; 3 days; MDA-MB-231 cells) treatment induces a dose-dependent decrease in cell proliferation of MDA-MB-231 cells (up to 40% inhibition at 25 ng/mL).
Cerivastatin sodium (25 ng/mL; 18-36 hours; MDA-MB-231 cells) treatment induces an arrest of the cell cycle in G 1/S phase after 36 h treatment. This arrest is not observed for a shorter incubation time (18 h).
Cerivastatin sodium (25 ng/mL; 18 hours; MDA-MB-231 cells) treatment induces a marked increase in the level of p21^Waf1/Cip1.
Cerivastatin sodium (25 ng/mL; 12 hours; MDA-MB-231 cells) treatment increases the p21 transcript in MDA-MB-231 cells.
Cerivastatin sodium (10-25 ng/mL; 18 hours) inhibits invasion of MDA-MB-231 cells through Matrigel.
Cerivastatin sodium (25 ng/mL; 18-36 hours) delocalizes RhoA and Ras from the membrane to the cytosol and induces morphological changes.
Cerivastatin sodium (25 ng/mL; 4-36 hours) induces inactivation of NFκB, in a RhoA inhibition-dependent manner, resulting in a decrease in urokinase and metalloproteinase-9 expression, and concomitantly increases IκB.

In Vivo: Cerivastatin sodium is well absorbed, reaching maximal plasma levels in 1-3 hours following oral dosing. In the circulation, Cerivastatin sodium is highly bound to plasma proteins (99.5%), with an elimination half-life of 2-4 hours. Cerivastatin is metabolized predominantly in the liver to three polar metabolites. Two of these metabolites are active, but to a lesser extent compared to parent drug, and the third metabolite is inactive. Plasma concentrations of all metabolites are substantially lower than those of the parent drug. Elimination of metabolites is via the urine (20-25%) and feces (66-73%), while essentially no parent compound is excreted.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Metabolism/Protease Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Drug Repurposing Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  Ferroptosis Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Cancer Metabolism Compound Library  |  Lipid Metabolism Compound Library   |  FDA-Approved Anticancer Drug Library  |  Heterocyclic Compound Library  |  Off-patent Drug Library  |  Cell Death Library  |  Ferrostatin-1  |  Erastin  |  Cisplatin  |  Cycloheximide  |  RSL3  |  Acetylcysteine  |  Sorafenib  |  ML385  |  Necrostatin-1  |  SP600125  |  Rosiglitazone  |  Liproxstatin-1  |  Curcumin  |  Simvastatin  |  Hemin  |  TBHQ  |  Lapatinib  |  Roxadustat  |  L-Glutathione reduced  |  Trolox  |  Lovastatin  |  Sulfasalazine  |  NADPH tetrasodium salt  |  U-73122  |  Pifithrin-α hydrobromide  |  Pioglitazone  |  iFSP1  |  Atorvastatin hemicalcium salt  |  FIN56  |  Baicalein

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds